Lilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Planning your retirement portfolio at 40? Discover essential assets to include for a balanced and secure financial future.
20,742 articlesEli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
As pay-TV declines, Comcast may lean on first-party data to power targeted streaming ads. This article breaks down ho...
Investors chasing steady monthly payouts in JEPQ face a trade-off: higher income amid lower long-run gains versus bro...
Broadcom stock rose on news of a strategic partnership update disclosed in a regulatory filing. This article breaks d...
A CFO selling a substantial stake can spark questions about a company’s short-term risk and long-term strategy. This ...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Investors are eyeing yuanbao (yb) 2026 earnings as the company pivots toward new revenue streams. This guide breaks d...
A founder sold a meaningful chunk of stock, but does that signal trouble or a routine liquidity move? This article br...
Palantir Technologies stock popped today on an earnings-tease event, not a full report. This article explains the dri...
CoreWeave has dropped substantially from its 52-week peak, leaving investors debating whether the bounce is coming or...
A new mega-listing grabbed headlines by raising $26.5 billion, ranking just below SpaceX in U.S. market history. Read...
The horizon ahead is dotted with questions about SoFi and its next investor update. This guide lays out a practical f...